Back to Search Start Over

The vulvar immunohistochemical panel (Vip) project: Molecular profiles of vulvar squamous cell carcinoma

Authors :
Garganese, Giorgia
Inzani, Frediano
Fragomeni, Simona Maria
Mantovani, G.
Corte, L. D.
Piermattei, Angelo
Santoro, Angela
Angelico, G.
Giaco, L.
Corrado, Giacomo
Fagotti, Anna
Zannoni, Gian Franco
Scambia, Giovanni
Garganese G. (ORCID:0000-0002-4209-5285)
Inzani F.
Fragomeni S. M.
Piermattei A. (ORCID:0000-0002-6835-1179)
Santoro A. (ORCID:0000-0002-6964-5152)
Corrado G.
Fagotti A. (ORCID:0000-0001-5579-335X)
Zannoni G. F. (ORCID:0000-0003-1809-129X)
Scambia G. (ORCID:0000-0003-2758-1063)
Garganese, Giorgia
Inzani, Frediano
Fragomeni, Simona Maria
Mantovani, G.
Corte, L. D.
Piermattei, Angelo
Santoro, Angela
Angelico, G.
Giaco, L.
Corrado, Giacomo
Fagotti, Anna
Zannoni, Gian Franco
Scambia, Giovanni
Garganese G. (ORCID:0000-0002-4209-5285)
Inzani F.
Fragomeni S. M.
Piermattei A. (ORCID:0000-0002-6835-1179)
Santoro A. (ORCID:0000-0002-6964-5152)
Corrado G.
Fagotti A. (ORCID:0000-0001-5579-335X)
Zannoni G. F. (ORCID:0000-0003-1809-129X)
Scambia G. (ORCID:0000-0003-2758-1063)
Publication Year :
2021

Abstract

Introduction: The study’s aim was to investigate the immunohistochemical (IHC) expression of biological markers as potential prognostic/therapeutic factors in vulvar squamous cell carcinoma (VSCC). Methodology: A series of 101 patients surgically treated at our center from 2016 to 2020 were retrospectively enrolled: 53 node-negative (Group A) and 48 node-positive (Group B). A total of 146 samples, 101 from primary tumor (T) and 45 from nodal metastases (N), were inves-tigated. The IHC panel included: p16, p53, MLH1, MSH2, MSH6, PMS2, PD-L1, CD3, HER2/neu, ER, PR, EGFR, VEGF, and CD31. The reactions were evaluated on qualitative and semi-quantitative scales. Generalized Linear Model (GLM) and cluster analysis were performed in R statistical en-vironment. A distance plot compared the IHC panel of T with the correspondent N. Results: In Group A: p16-positive expression (surrogate of HPV-dependent pathway) was significantly higher (20.8% vs. 6.2%, p = 0.04). In Group B: PD-L1 positivity and high EGFR expression were found, respectively, in 77.1% and 97.9% patients (T and/or N). Overall, p16-negative tumors showed a higher PD-L1 expression (60.9% vs. 50.0%). In both groups: tumoral immune infiltration (CD3 expression) was mainly moderate/intense (80% vs. 95%); VEGF showed strong/moderate-diffuse expression in 13.9% of T samples; CD31, related to tumoral microvessel density (MVD), showed no difference between groups; a mutated p53 and over-expressed PD-L1 showed significant association with nodal metastasis, with Odds Ratios (OR) of 4.26 (CI 95% = 1.14–15.87, p = 0.03) and 2.68 (CI 95% = 1.0–7.19, p < 0.05), respectively; since all mismatch repair proteins (MMR) showed a retained expression and ER, PR, and HER2/neu were negative, they were excluded from further analysis. The cluster analysis identified three and four sub-groups of molecular profiles, respectively, in Group A and B, with no difference in prognosis. The molecular signature of each N and corresponding T d

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1330708585
Document Type :
Electronic Resource